ArticleCNS neuroscience & therapeutics2026
Improved Method for Obtaining Patient-Derived Glioblastoma Organoid and Primary Cells: A Generic and Simplified Approach for Intracranial Tumor With Minimized Input.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionGlioblastoma is one of the most malignant primary tumors in adults. The shortages of the traditional tumor models obstruct the development of basic research and therapeutic modes. Application of organoid is critical to keep tumoral heterogeneity and microenvironment. The current method for generating glioblastoma organoid is sophisticated, laborious, and inconvenient.
methodsWe collected glioblastoma tissue samples from patients and used an improved methodology to generate organoids. Subsequently, the collected suspension during the process was used to isolate primary tumor cells. Organoid were used to assess its drug susceptibility. Finally, we generated organoids of other CNS tumors with the same method.
resultsThe improved method took less time and lowered technical requirements. Glioblastoma organoids generated with our improved method can be cultured for further research. Primary glioblastoma cells isolated from collected medium were proved with immunofluorescence. Patient-derived glioblastoma organoids showed consistent drug susceptibility with the patients. Tumor organoids were also generated successfully from patient's lymphoma and low-grade glioma samples.
conclusionsWe improved an easier and rapider method to generate glioma organoids from tissue samples and avoided wasting primary tumor cells in used medium. This method established a technical foundation for the widely application of organoids in neuro-oncology tumor research and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.